Skip to main content

Breast Cancer

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

Breast Cancer, Pediatric Oncology, Multiple Myeloma, FDA Approvals, News & Updates

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

FDA Approvals, News & Updates, Breast Cancer

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, News & Updates

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Breast Cancer, FDA Approvals, News & Updates

Practice-Changing Results: Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer

Breast Cancer, Web Exclusives

Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer

Breast Cancer, Web Exclusives

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

Breast Cancer, Web Exclusives

Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is In the Details

Breast Cancer, Web Exclusives

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

Breast Cancer, Web Exclusives

State of Personalized Medicine in Breast Cancer

By Sarika Jain; Sachin G. Pai; Cesar A. Santa-Maria; William J. Gradishar

Page 1 of 2

1
2